FibroGen Inc (OQ:FGEN)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 409 ILLINOIS STREET
SAN FRANCISCO CA 94158
Tel: N/A
Website: https://www.fibrogen.com
IR: See website
<
Key People
Thane Wettig
Chief Executive Officer, Director, Chief Commercial Officer
Juan Graham
Chief Financial Officer
Deyaa Adib
Senior Vice President and Chief Medical Officer
Christine L. Chung
Senior Vice President, China Operations
   
Business Overview
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.
Financial Overview
For the three months ended 31 March 2024, FibroGen Inc revenues increased 55% to $55.9M. Net loss decreased 57% to $32.9M. Revenues reflect Drug product revenue increase from $2.1M to $24.5M, Product revenue increase of 26% to $30.5M. Lower net loss reflects Research and Development decrease of 48% to $38.4M (expense), General and Administrative decrease of 33% to $22.8M (expense).
Employees: 486 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $28.29M as of Mar 31, 2024
Annual revenue (TTM): $167.49M as of Mar 31, 2024
EBITDA (TTM): -$216.40M as of Mar 31, 2024
Net annual income (TTM): -$240.46M as of Mar 31, 2024
Free cash flow (TTM): -$274.68M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 99,475,398 as of Apr 30, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.